PE20191662A1 - Anticuerpos anti-il-5 - Google Patents
Anticuerpos anti-il-5Info
- Publication number
- PE20191662A1 PE20191662A1 PE2019001295A PE2019001295A PE20191662A1 PE 20191662 A1 PE20191662 A1 PE 20191662A1 PE 2019001295 A PE2019001295 A PE 2019001295A PE 2019001295 A PE2019001295 A PE 2019001295A PE 20191662 A1 PE20191662 A1 PE 20191662A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- sequence
- antibody
- mutation
- heavy chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Referido a un anticuerpo humano, el cual se une inmunoespecificamente a IL-5 humana, que comprende: una CDR1 de cadena pesada que comprende la secuencia de SEQ ID NO: 4; una CDR2 de cadena pesada que comprende la secuencia de SEQ ID NO: 6; una CDR3 de cadena pesada que comprende la secuencia de SEQ ID NO: 8; una CDR1 de cadena ligera que comprende la secuencia de SEQ ID NOs: 5, 21, 24, 27, 30, 33, 36, 39 o 66, una CDR2 de cadena ligera que comprende la secuencia de SEQ ID NOs: 7, 42 o 45, y una CDR3 de cadena ligera que comprende la secuencia de SEC ID NOs: 15, 48, 51, 54, 57, 60 o 63. Ademas, dicho anticuerpo comprende: a) una mutacion S228P; b) una mutacion M252Y, una mutacion S254T y una mutacion T256E; c) una supresion de residuo de lisina C-terminal de cadena pesada; o d) cualquier combinacion de a hasta c. Dicho anticuerpo se caracteriza por reducir la union de IL-5 al receptor de IL-5 y tener una vida media serica de al menos aproximadamente 20 dias; siendo util en el tratamiento del asma eosinofilica, el sindrome hipereosinofilico, entre otros. Tambien se refiere a una molecula de acido nucleico, un vector, una celula huesped que codifica dicho anticuerpo y una composicion farmaceutica que comprende dicho anticuerpo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438502P | 2016-12-23 | 2016-12-23 | |
| PCT/US2017/067475 WO2018119016A1 (en) | 2016-12-23 | 2017-12-20 | Anti-il-5 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191662A1 true PE20191662A1 (es) | 2019-11-11 |
Family
ID=60972458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001295A PE20191662A1 (es) | 2016-12-23 | 2017-12-20 | Anticuerpos anti-il-5 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11111292B2 (es) |
| EP (1) | EP3559030B1 (es) |
| JP (1) | JP7060906B2 (es) |
| KR (1) | KR102651290B1 (es) |
| CN (1) | CN110267986B (es) |
| AR (1) | AR110564A1 (es) |
| AU (1) | AU2017379853A1 (es) |
| BR (1) | BR112019012929A2 (es) |
| CA (1) | CA3048186A1 (es) |
| CL (1) | CL2019001730A1 (es) |
| EA (1) | EA201991552A1 (es) |
| IL (1) | IL267271A (es) |
| MX (1) | MX2019007642A (es) |
| NZ (1) | NZ754606A (es) |
| PE (1) | PE20191662A1 (es) |
| PH (1) | PH12019501452A1 (es) |
| RU (1) | RU2758008C2 (es) |
| WO (1) | WO2018119016A1 (es) |
| ZA (1) | ZA201904097B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117018190A (zh) | 2017-05-26 | 2023-11-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物制药组合物和相关方法 |
| CN113366016B (zh) * | 2018-12-12 | 2022-12-16 | 上海开拓者生物医药有限公司 | 抗人白细胞介素5(il-5)单克隆抗体及其应用 |
| AU2020251627A1 (en) | 2019-03-29 | 2021-11-11 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing antibody against IL-5 and use thereof |
| CN112745389B (zh) * | 2019-10-29 | 2022-11-25 | 瑞阳(苏州)生物科技有限公司 | 结合人il-5的单克隆抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| AU708951B2 (en) * | 1994-12-23 | 1999-08-19 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| CA2479927C (en) | 2002-03-29 | 2013-03-12 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| AU2016311385C1 (en) | 2015-08-24 | 2019-08-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Biopharmaceutical compositions |
-
2017
- 2017-12-20 AU AU2017379853A patent/AU2017379853A1/en active Pending
- 2017-12-20 AR ARP170103611A patent/AR110564A1/es unknown
- 2017-12-20 NZ NZ754606A patent/NZ754606A/en unknown
- 2017-12-20 BR BR112019012929A patent/BR112019012929A2/pt unknown
- 2017-12-20 JP JP2019534656A patent/JP7060906B2/ja active Active
- 2017-12-20 EA EA201991552A patent/EA201991552A1/ru unknown
- 2017-12-20 EP EP17829503.6A patent/EP3559030B1/en active Active
- 2017-12-20 RU RU2019123112A patent/RU2758008C2/ru active
- 2017-12-20 WO PCT/US2017/067475 patent/WO2018119016A1/en unknown
- 2017-12-20 PE PE2019001295A patent/PE20191662A1/es unknown
- 2017-12-20 MX MX2019007642A patent/MX2019007642A/es unknown
- 2017-12-20 CA CA3048186A patent/CA3048186A1/en active Pending
- 2017-12-20 KR KR1020197021088A patent/KR102651290B1/ko active IP Right Grant
- 2017-12-20 CN CN201780079923.2A patent/CN110267986B/zh active Active
- 2017-12-20 US US15/848,090 patent/US11111292B2/en active Active
-
2019
- 2019-06-12 IL IL267271A patent/IL267271A/en unknown
- 2019-06-20 CL CL2019001730A patent/CL2019001730A1/es unknown
- 2019-06-21 PH PH12019501452A patent/PH12019501452A1/en unknown
- 2019-06-24 ZA ZA2019/04097A patent/ZA201904097B/en unknown
-
2021
- 2021-07-26 US US17/385,532 patent/US20210355205A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11111292B2 (en) | 2021-09-07 |
| US20210355205A1 (en) | 2021-11-18 |
| US20180186873A1 (en) | 2018-07-05 |
| CL2019001730A1 (es) | 2019-09-27 |
| ZA201904097B (en) | 2023-12-20 |
| RU2019123112A (ru) | 2021-01-26 |
| RU2019123112A3 (es) | 2021-04-05 |
| CN110267986B (zh) | 2023-05-09 |
| JP2020513761A (ja) | 2020-05-21 |
| BR112019012929A2 (pt) | 2019-12-10 |
| KR20190126769A (ko) | 2019-11-12 |
| RU2758008C2 (ru) | 2021-10-25 |
| KR102651290B1 (ko) | 2024-03-25 |
| EA201991552A1 (ru) | 2020-01-09 |
| NZ754606A (en) | 2023-06-30 |
| AU2017379853A1 (en) | 2019-07-04 |
| IL267271A (en) | 2019-08-29 |
| CN110267986A (zh) | 2019-09-20 |
| EP3559030A1 (en) | 2019-10-30 |
| JP7060906B2 (ja) | 2022-04-27 |
| EP3559030B1 (en) | 2024-04-03 |
| CA3048186A1 (en) | 2018-06-28 |
| AR110564A1 (es) | 2019-04-10 |
| PH12019501452A1 (en) | 2020-06-15 |
| EP3559030C0 (en) | 2024-04-03 |
| MX2019007642A (es) | 2019-09-09 |
| WO2018119016A1 (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191662A1 (es) | Anticuerpos anti-il-5 | |
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| CO2019006657A2 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| JP2018524326A5 (es) | ||
| PE20240096A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
| PE20190440A1 (es) | Anticuerpos a la alfa-sinucleina y usos de los mismos | |
| PE20190920A1 (es) | Anticuerpos modificados de union a fcrn humano y metodos de utilizacion | |
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| RU2022101604A (ru) | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином | |
| AR075047A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. | |
| PE20120415A1 (es) | Anticuerpos anti-igf | |
| CR20140029A (es) | Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada | |
| HRP20201392T1 (hr) | Fgf21 fuzijski proteini dugotrajnog djelovanja i farmaceutski pripravci koji sadrže iste | |
| AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| CL2013001279A1 (es) | Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso. | |
| JP2017527272A5 (es) | ||
| CL2008002668A1 (es) | Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp. | |
| JP2017532037A (ja) | ヒト化抗ｏｘ４０抗体及びその使用 | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| PE20120832A1 (es) | Proteinas de union al antigeno del receptor a de la il-17 | |
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba |